Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-label, Single-center Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy

NCT02987114 is registered in ClinicalTrials.gov with PhytoTech Therapeutics, Ltd. as lead sponsor.

NCT NCT02987114
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987114 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-label, Single-center Clinical Study to Evaluate the Safety, Tolerability and Efficacy of Oral Administration of PTL101 (Cannabidiol) as an Adjunctive Treatment for Pediatric Intractable Epilepsy
Lead sponsor
PhytoTech Therapeutics, Ltd.
Phase
Phase 2
Overall status
Completed
Start date
February 13, 2017
Completion date
June 28, 2018
Enrollment
16 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsy intractable